Volume 4, Issue 1

HIV Therapies: Newly Approved and in the Pipeline

In this issue:

Ongoing research has led to new therapies — both newly approved and in the pipeline — for patients with HIV infection. Treatment options are rapidly increasing, including new drugs with novel mechanisms, less frequent dosing strategies, long-acting ART, and investigational duotherapies.

 

In this issue, Dr. Ethel Weld from the Division of Clinical Pharmacology and the Division of Infectious Diseases at Johns Hopkins University School of Medicine explains how the new therapies available or in late-stage development can help clinicians improve their management of their patients infected with the HIV virus.

Learning objectives:

After participating in this activity, the participant will demonstrate the ability to:

  • Describe some of the seminal clinical trials and evidence bases behind newly approved and emerging therapies for HIV.
  • Explain how new therapies can be used in treating HIV, including relevant dosing, side effects, resistance, and adherence considerations.
  • Summarize the current and potential future role for less frequent dosing strategies, duotherapy, and long-acting antiretrovirals (ART) in treating HIV.

Author:

Ethel D. Weld, MD
Ethel D. Weld, MD
Assistant Professor of Medicine, Pharmacology, & Molecular Sciences
Division of Clinical Pharmacology & Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Program Directors:

Allison L. Agwu, MD, ScM, FAAP, FIDSA
Associate Professor of Pediatrics and Adult Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Alysse G. Wurcel, MD, MS
Assistant Professor
Division of Geographic Medicine and Infectious Diseases
Tufts Medical Center
Boston, Massachusetts

Justin Alves, RN, ACRN, CARN
Infectious Disease Associates
Massachusetts General Hospital
Boston, Massachusetts

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: August 31, 2018
Expiration date: August 30, 2020

Sign-In

Not a subscriber? Start here!